How I manage patients with inherited haemophilia A and B and factor inhibitors
Ljung, Rolf C.R. LU
(2018)
In British Journal of Haematology
180(4).
p.501-510
- Abstract
Development of inhibitors to coagulation factor VIII or IX is still the most challenging complication in haemophilia care. 'Bypassing agents' may be used to treat a bleed but the eradication of the inhibitor by immune tolerance induction (ITI) is the main objective in the treatment of a patient with haemophilia who has developed neutralizing antibodies. Several options exist for ITI and the patient may be at 'good' or 'bad risk' for successful outcome with different regimens. This paper offers a review of current regimens to be considered in the treatment of a bleed in a patient with an inhibitor but the main focus is the aspects of different choices in the management of the child or the adult with severe or mild forms of haemophilia A... (More)
Development of inhibitors to coagulation factor VIII or IX is still the most challenging complication in haemophilia care. 'Bypassing agents' may be used to treat a bleed but the eradication of the inhibitor by immune tolerance induction (ITI) is the main objective in the treatment of a patient with haemophilia who has developed neutralizing antibodies. Several options exist for ITI and the patient may be at 'good' or 'bad risk' for successful outcome with different regimens. This paper offers a review of current regimens to be considered in the treatment of a bleed in a patient with an inhibitor but the main focus is the aspects of different choices in the management of the child or the adult with severe or mild forms of haemophilia A or B, who has developed an inhibitor. There are also some final outlooks on new and emerging treatment possibilities.
(Less)
- author
- Ljung, Rolf C.R.
LU
- organization
- publishing date
- 2018-02
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Factor IX, Factor VIII, Haemophilia, Immune tolerance induction, Inhibitors
- in
- British Journal of Haematology
- volume
- 180
- issue
- 4
- pages
- 501 - 510
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:29270992
- scopus:85038840406
- ISSN
- 0007-1048
- DOI
- 10.1111/bjh.15053
- language
- English
- LU publication?
- yes
- id
- ab634bd5-7099-4d0a-bb88-b38b1d695628
- date added to LUP
- 2018-01-10 16:21:06
- date last changed
- 2024-04-14 23:43:51
@article{ab634bd5-7099-4d0a-bb88-b38b1d695628,
abstract = {{<p>Development of inhibitors to coagulation factor VIII or IX is still the most challenging complication in haemophilia care. 'Bypassing agents' may be used to treat a bleed but the eradication of the inhibitor by immune tolerance induction (ITI) is the main objective in the treatment of a patient with haemophilia who has developed neutralizing antibodies. Several options exist for ITI and the patient may be at 'good' or 'bad risk' for successful outcome with different regimens. This paper offers a review of current regimens to be considered in the treatment of a bleed in a patient with an inhibitor but the main focus is the aspects of different choices in the management of the child or the adult with severe or mild forms of haemophilia A or B, who has developed an inhibitor. There are also some final outlooks on new and emerging treatment possibilities.</p>}},
author = {{Ljung, Rolf C.R.}},
issn = {{0007-1048}},
keywords = {{Factor IX; Factor VIII; Haemophilia; Immune tolerance induction; Inhibitors}},
language = {{eng}},
number = {{4}},
pages = {{501--510}},
publisher = {{Wiley-Blackwell}},
series = {{British Journal of Haematology}},
title = {{How I manage patients with inherited haemophilia A and B and factor inhibitors}},
url = {{http://dx.doi.org/10.1111/bjh.15053}},
doi = {{10.1111/bjh.15053}},
volume = {{180}},
year = {{2018}},
}